We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Latest Industry Insights
How Can AI Techniques Improve How We Diagnose Dementia?
Industry Insight

How Can AI Techniques Improve How We Diagnose Dementia?

Developing treatments for dementia remains one of the most forbidding challenges facing neurology. Traditionally, paper-based assessments are used by clinicians to diagnose patients. But London-based company Cognetivity says that its AI-based platform could improve diagnostics. We spoke with the company’s co-founder and chief science officer, Dr. Seyed Khaligh-Razavi, to find out more.
How Can We Make It Easier To Implant a Brain-Computer Interface?
Industry Insight

How Can We Make It Easier To Implant a Brain-Computer Interface?

Brain-computer interfaces (BCI) have the potential to revolutionize the lives of people with severe motor and nervous system impairments. But users of current BCI technology must face the hurdle of implanting the device in their brain. We spoke to Professor Florian Solzbacher, co-founder and chairman of Blackrock, to find out more about how neurotechnology companies are overcoming this obstacle.
Accelerating Biological Discovery With Open-Source Spatial Genomics Data
Industry Insight

Accelerating Biological Discovery With Open-Source Spatial Genomics Data

In this interview, Dr. George Emanuel discusses some of the most exciting findings from the Mouse Receptor Map and highlights how the datasets will benefit the Human Cell Atlas project.
Revolutionizing the Science of Nerve Repair and Regeneration
Industry Insight

Revolutionizing the Science of Nerve Repair and Regeneration

To learn more about the causes and consequences of peripheral nerve damage and some of the solutions available to patients, Technology Networks spoke with Karen Zaderej, chief executive officer of Axogen.
The Value of Investing in Sex- and Gender-Based Alzheimer’s Disease Research
Industry Insight

The Value of Investing in Sex- and Gender-Based Alzheimer’s Disease Research

Women’s Health Access Matters recently released The WHAM Report, outlining new research conducted by the RAND Corporation to study the impact of accelerating sex- and gender-based AD, heart and autoimmune research on women, their families and the economy. To learn more about the report, the recently released AD findings and their significance, we spoke to Carolee Lee, founder and CEO of WHAM.
Cancer Research: Potential Key To Unlocking Alzheimer’s Disease Therapies
Industry Insight

Cancer Research: Potential Key To Unlocking Alzheimer’s Disease Therapies

In the search to discover new therapeutic approaches for AD, scientists are finding new inspiration where others may have never thought to look: cancer research trends.
A “Living Pharmacy” That Can Shift the Body’s Circadian Clock
Industry Insight

A “Living Pharmacy” That Can Shift the Body’s Circadian Clock

Many of us are familiar with the undesirable physical and mental effects of a disrupted sleep/wake cycle caused by traveling across multiple time zones or working irregular hours. A collaborative project designed to address these issues is working to develop a “living pharmacy” – a personalized, wireless and fully implantable device that can control the body’s circadian clock.
Could Fly Agaric Mushroom Compound Muscimol Be a Successful Psychedelic?
Industry Insight

Could Fly Agaric Mushroom Compound Muscimol Be a Successful Psychedelic?

Technology Networks recently spoke with Jeff Stevens, Psyched Wellness’s CEO, to learn more about muscimol, its therapeutic potential and how it compares to other psychedelics such as psilocybin.
Interview: Behind the E-mmunotherapy Earbud That Could Treat Arthritis
Industry Insight

Interview: Behind the E-mmunotherapy Earbud That Could Treat Arthritis

Non-invasive stimulation company Nēsos recently announced that its “e-mmunotherapy” earbud has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for patients with rheumatoid arthritis (RA). We spoke to Konstantinos Alataris, president and CEO of Nēsos, to find out more about the company's device and its potential applications.
Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry
Industry Insight

Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry

In this interview, David E. Olson discusses the potential commercial, clinical and scientific implications of non-hallucinogenic psychedelic compounds.
Advertisement